Brian Tanquilut

Kenny cited a vibrant cash market plus strong growth in the covered segment, saying the coverage debate has not meaningfully slowed the category's healthy growth.

Britt confirmed GLP-1 distribution growth in mid-20% range for past several years and strong demand for prior authorization and affordability services with adjacent product expansion.

Britt deferred full FY2027 outlook to the Q4 call but highlighted positive building blocks: stable utilization, strong specialty growth, operating efficiency with 138 bps OpEx/GP improvement. Noted 24% organic revenue growth and 15% organic OP growth in O&M with quarter-to-quarter mix variability.

Britt explained 3 nonrecurring items occurred in Q2, most known at Investor Day, with one item's timing shifted from back half. Organic O&M growth of 13% in line with long-term guidance. Acquisitions contributing approximately half of OP growth.

Britt described a multi-year journey of improving operating leverage through discipline, automation, and process improvement but declined to quantify specific future OpEx impact.

Brian emphasized leading alternate-site position and focus on wallet share over market share. Britt confirmed PRISM is not currently a distribution customer, making it incremental.

Britt framed biosimilars as a margin and value opportunity, especially in Part B oncology and specialty.

Marks confirmed the provider tax driver, pivoted to total cost per adjusted admission being flat to slightly up, and quantified professional fees at 8.5%.

Mike declined to give quarterly guidance but emphasized Q1 volume shortfall was temporal and pointed to exchange dynamics still being studied.

Mike noted Rural Health Transformation Fund allocated but state-level details pending, not in guidance. Q4 only divergence was Virginia retro payment pushing supplemental flat vs expected decline. Sam added ~15% of HCA hospitals are rural.

Mike outlined three supply levers: contract renewals (2-3 year cycles), technology mix management, and utilization management. Sam expanded on holistic resiliency across financial, organizational, and network dimensions.

Sam confirmed sustained market share gains above 28% ex-behavioral health. $5.5B capital in flight adding network capacity. Completed midyear division reviews with optimistic market assessments.

Mike confirmed $991M Q1 CapEx was timing-related, still targeting $5-5.2B for year. On buybacks, completed $2.5B in Q1 and anticipates significant portion of $10B authorization in 2025.

Yemi attributed the wide EBITDA range to stage-gated investment flexibility across new specialties, technology and international expansion.

Okupe framed buybacks as opportunistic when market value diverges from intrinsic value, but growth investment stays the first priority given strong FCF and balance sheet.

Yemi committed to robust H2 marketing investment while holding a sub-1-year payback under the capital allocation framework, funding new specialties, geographies and AI talent.

Yemi framed the inventory build as a one-off to secure supply for new specialties amid global tariff volatility, not a recurring quarterly step-up.

Aaron reiterated $1B BioPharma Services target by FY28 with 30%+ growth this year, half from Sonexus. Don't separately break out sub-components. Continuing investment across Sonexus hub, Cell and Gene, 3PL to support broader specialty growth objective.

Jason attributed Sonexus growth to breadth of new product launches (40 expected in CY25, growth of 30%+) rather than any single service. Part of BioPharma Solutions expected to grow from $550M in FY25 to ~$1B by FY28. Promised more color in future quarters.

Jason noted historical precedent is mixed, sometimes inflationary benefit, sometimes buy/sell move in tandem. Consistent market dynamics assumed going forward.